Acipimox
Acipimox is a niacin derivative that acts as an anti-hyperlipidemic. Acipimox decreases levels of triglycerides, LDL, and free fatty acids, and increases levels of HDL. Acipimox decreases cAMP levels and AMPK activity, suppressing lipolysis by lipase.
References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18835747
| Cas No. |
51037-30-0 |
|---|---|
| Purity |
≥98% |
| Formula |
C6H6N2O3 |
| Formula Wt. |
154.12 |
| Chemical Name |
5-Methylpyrazinecarboxylic acid 4-oxide |
| IUPAC Name |
5-methyl-4-oxidopyrazin-4-ium-2-carboxylic acid |
| Melting Point |
177-180°C |
| Solubility |
Water 20 mg/mL |
| Appearance |
Off-white crystalline powder |
Møller N, Gormsen LC, Schmitz O, et al. Free fatty acids inhibit growth hormone/signal transducer and activator of transcription-5 signaling in human muscle: a potential feedback mechanism. J Clin Endocrinol Metab. 2009 Jun;94(6):2204-7. PMID: 19276230.
Christie AW, McCormick DK, Emmison N, et al. Mechanism of anti-lipolytic action of acipimox in isolated rat adipocytes. Diabetologia. 1996 Jan;39(1):45-53. PMID: 8720602.
